Skip to main content
Top
Published in: Pituitary 5/2014

01-10-2014

GH secretion reserve in subclinical hypercortisolism

Authors: Serena Palmieri, Valentina Morelli, Antonio Stefano Salcuni, Cristina Eller-Vainicher, Elisa Cairoli, Volha V. Zhukouskaya, Paolo Beck-Peccoz, Alfredo Scillitani, Iacopo Chiodini

Published in: Pituitary | Issue 5/2014

Login to get access

Abstract

Purpose

In overt hypercortisolism, growth hormone (GH) secretion is decreased and normalizes after surgery. In subclinical hypercortisolism (SH), GH secretion has been scarcely investigated. We assessed GH reserve in patients with and without SH and, in the former, also after recovery.

Methods

We enrolled 24 patients with adrenal adenomas, 12 with SH (SH+, 8 females, 58.3 ± 6.5 years) and 12 without SH (SH−; 11 females, 61.8 ± 10.6 years). SH was diagnosed in the presence of ≥2 out of: 1 mg overnight dexamethasone suppression test >83 nmol/L, urinary free cortisol (UFC) >193 nmol/day and ACTH levels <2.2 pmol/L. GH secretion was assessed by GHRH + Arginine test (GHRH–ARG) and age-adjusted serum IGF-I levels, expressed as SDS (IGF-I SDS). Eight SH+ patients were re-evaluated after the recovery from SH.

Results

Age, gender, body mass index (BMI) and IGF-I SDS were comparable between SH+ and SH− patients. After GHRH–ARG the mean GH peak levels (GH-P) and GH response (as Area Under Curve, GH-AUC) were lower in SH+ than in SH− patients (15.2 ± 8.1 vs 44.5 ± 30.9 μg/L, P = 0.004 and 1,418 ± 803 vs 4,028 ± 2,476 μg/L/120 min, P = 0.002, respectively), after adjusting for age and BMI. The GH-AUC and GH-P levels were negatively associated with UFC after adjusting for age and BMI (β = −0.39, P = 0.02 and β = −0.4, P = 0.020 respectively). After recovery, GH-P levels and GH-AUC increased as compared to baseline (23.7 ± 16.3 vs 15.8 ± 10.2 μg/L, P = 0.036 and 2,549 ± 1,982 vs 1,618 ± 911 μg/L/120 min, P = 0.012, respectively).

Conclusions

GH secretion reserve is decreased in SH patients and increases after the recovery.
Literature
1.
go back to reference Burguera B, Muruais C, Peñalva A, Dieguez C, Casanueva FF (1990) Dual and selective actions of glucocorticoids upon basal and stimulated growth hormone release in man. Neuroendocrinology 51:51–58PubMedCrossRef Burguera B, Muruais C, Peñalva A, Dieguez C, Casanueva FF (1990) Dual and selective actions of glucocorticoids upon basal and stimulated growth hormone release in man. Neuroendocrinology 51:51–58PubMedCrossRef
2.
go back to reference Smals AE, Pieters GF, Smals AG, Benraad TJ, Kloppenborg PW (1986) Human pancreatic growth hormone releasing hormone fails to stimulate human growth hormone both in Cushing’s disease and in Cushing’s syndrome due to adrenocortical adenoma. Clin Endocrinol (Oxf) 24:401–407CrossRef Smals AE, Pieters GF, Smals AG, Benraad TJ, Kloppenborg PW (1986) Human pancreatic growth hormone releasing hormone fails to stimulate human growth hormone both in Cushing’s disease and in Cushing’s syndrome due to adrenocortical adenoma. Clin Endocrinol (Oxf) 24:401–407CrossRef
3.
go back to reference Leal-Cerro A, Pumar A, Garcia–Garcia E, Dieguez C, Casanueva FF (1994) Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing’s syndrome. Clin Endocrinol (Oxf) 41:649–654CrossRef Leal-Cerro A, Pumar A, Garcia–Garcia E, Dieguez C, Casanueva FF (1994) Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing’s syndrome. Clin Endocrinol (Oxf) 41:649–654CrossRef
5.
go back to reference Wehrenberg WB, Bergman PJ, Stagg L, Ndon J, Giustina A (1990) Glucocorticoid inhibition of growth in rats: partial reversal with somatostatin antibodies. Endocrinology 127:2705–2708PubMedCrossRef Wehrenberg WB, Bergman PJ, Stagg L, Ndon J, Giustina A (1990) Glucocorticoid inhibition of growth in rats: partial reversal with somatostatin antibodies. Endocrinology 127:2705–2708PubMedCrossRef
6.
go back to reference Leal-Cerro A, Soto A, Martínez MA, Alvarez P, Isidro L, Casanueva FF, Dieguez C, Cordido F (2002) Effect of withdrawal of somatostatin plus growth hormone (GH)-releasing hormone as a stimulus of GH secretion in Cushing’s syndrome. Clin Endocrinol (Oxf) 57:745–749CrossRef Leal-Cerro A, Soto A, Martínez MA, Alvarez P, Isidro L, Casanueva FF, Dieguez C, Cordido F (2002) Effect of withdrawal of somatostatin plus growth hormone (GH)-releasing hormone as a stimulus of GH secretion in Cushing’s syndrome. Clin Endocrinol (Oxf) 57:745–749CrossRef
7.
go back to reference Giustina A, Veldhuis JD (1998) Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19:717–797PubMed Giustina A, Veldhuis JD (1998) Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19:717–797PubMed
8.
go back to reference Tzanela M, Karavitaki N, Stylianidou C, Tsagarakis S, Thalassinos NC (2004) Assessment of GH reserve before and after successful treatment of adult patients with Cushing’s syndrome. Clin Endocrinol (Oxf) 60:309–314CrossRef Tzanela M, Karavitaki N, Stylianidou C, Tsagarakis S, Thalassinos NC (2004) Assessment of GH reserve before and after successful treatment of adult patients with Cushing’s syndrome. Clin Endocrinol (Oxf) 60:309–314CrossRef
9.
go back to reference Mukherjee A, Murray RD, Teasdale GM, Shalet SM (2004) Acquired prolactin deficiency (APD) after treatment for Cushing’s disease is a reliable marker of irreversible severe GHD but does not reflect disease status. Clin Endocrinol (Oxf) 60:476–483CrossRef Mukherjee A, Murray RD, Teasdale GM, Shalet SM (2004) Acquired prolactin deficiency (APD) after treatment for Cushing’s disease is a reliable marker of irreversible severe GHD but does not reflect disease status. Clin Endocrinol (Oxf) 60:476–483CrossRef
10.
11.
go back to reference Chiodini I (2011) Clinical review: diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab 96:1223–1236PubMedCrossRef Chiodini I (2011) Clinical review: diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab 96:1223–1236PubMedCrossRef
12.
go back to reference Terzolo M, Pia A, Alì A, Osella G, Reimondo G, Bovio S, Daffara F, Procopio M, Paccotti P, Borretta G, Angeli A (2002) Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab 87:998–1003PubMedCrossRef Terzolo M, Pia A, Alì A, Osella G, Reimondo G, Bovio S, Daffara F, Procopio M, Paccotti P, Borretta G, Angeli A (2002) Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab 87:998–1003PubMedCrossRef
13.
go back to reference Chiodini I, Morelli V, Masserini B, Salcuni AS, Eller-Vainicher C, Viti R, Coletti F, Guglielmi G, Battista C, Carnevale V, Iorio L, Beck-Peccoz P, Arosio M, Ambrosi B, Scillitani A (2009) Bone mineral density, prevalence of vertebral fractures and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: an Italian Multicenter Study. J Clin Endocrinol Metab 94:3207–3214PubMedCrossRef Chiodini I, Morelli V, Masserini B, Salcuni AS, Eller-Vainicher C, Viti R, Coletti F, Guglielmi G, Battista C, Carnevale V, Iorio L, Beck-Peccoz P, Arosio M, Ambrosi B, Scillitani A (2009) Bone mineral density, prevalence of vertebral fractures and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: an Italian Multicenter Study. J Clin Endocrinol Metab 94:3207–3214PubMedCrossRef
14.
go back to reference Chiodini I, Torlontano M, Scillitani A, Arosio M, Bacci S, Di Lembo S, Epaminonda P, Augello G, Enrini R, Ambrosi B, Adda G, Trischitta V (2005) Association of subclinical hypercortisolism with type 2 diabetes mellitus: a case-control study in hospitalized patients. Eur J Endocrinol 15:837–844CrossRef Chiodini I, Torlontano M, Scillitani A, Arosio M, Bacci S, Di Lembo S, Epaminonda P, Augello G, Enrini R, Ambrosi B, Adda G, Trischitta V (2005) Association of subclinical hypercortisolism with type 2 diabetes mellitus: a case-control study in hospitalized patients. Eur J Endocrinol 15:837–844CrossRef
15.
go back to reference Terzolo M, Osella G, Alì A, Borretta G, Cesario F, Paccotti P, Angeli A (1998) Subclinical Cushing’s syndrome in adrenal incidentaloma. Clinical Endocrinol (Oxf) 48:89–97CrossRef Terzolo M, Osella G, Alì A, Borretta G, Cesario F, Paccotti P, Angeli A (1998) Subclinical Cushing’s syndrome in adrenal incidentaloma. Clinical Endocrinol (Oxf) 48:89–97CrossRef
16.
go back to reference Terzolo M, Bossoni S, Alí A, Doga M, Reimondo G, Milani G, Peretti P, Manelli F, Angeli A, Giustina A (2000) Growth hormone (GH) responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone. J Clin Endocrinol Metab 85:1310–1315PubMedCrossRef Terzolo M, Bossoni S, Alí A, Doga M, Reimondo G, Milani G, Peretti P, Manelli F, Angeli A, Giustina A (2000) Growth hormone (GH) responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone. J Clin Endocrinol Metab 85:1310–1315PubMedCrossRef
17.
go back to reference Tzanela M, Zianni D, Stylianidou Ch, Karavitaki N, Tsagarakis S, Thalassinos NC (2005) Evaluation of GH reserve in patients with adrenal incidentalomas and biochemical evidence of subclinical autonomous glucocorticoid hypersecretion. Clin Endocrinol (Oxf) 62:597–602CrossRef Tzanela M, Zianni D, Stylianidou Ch, Karavitaki N, Tsagarakis S, Thalassinos NC (2005) Evaluation of GH reserve in patients with adrenal incidentalomas and biochemical evidence of subclinical autonomous glucocorticoid hypersecretion. Clin Endocrinol (Oxf) 62:597–602CrossRef
18.
go back to reference Murray RD, Adams JE, Shalet SM (2004) Adults with partial growth hormone deficiency have an adverse body composition. J Clin Endocrinol Metab 89:1586–1591PubMedCrossRef Murray RD, Adams JE, Shalet SM (2004) Adults with partial growth hormone deficiency have an adverse body composition. J Clin Endocrinol Metab 89:1586–1591PubMedCrossRef
19.
go back to reference Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML (2011) Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1587–1609PubMedCrossRef Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML (2011) Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1587–1609PubMedCrossRef
20.
go back to reference NIH state-of-the-science statement on management of the clinically inapparent adrenal mass (“incidentaloma”) (2002) NIH Consens. State Sci Statements 19: 1–25 NIH state-of-the-science statement on management of the clinically inapparent adrenal mass (“incidentaloma”) (2002) NIH Consens. State Sci Statements 19: 1–25
21.
go back to reference Ho KK (2007) 2007 GH deficiency consensus workshop participants consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH research society in association with the European society for Pediatric Endocrinology, Lawson Wilkins society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 157:695–700PubMedCrossRef Ho KK (2007) 2007 GH deficiency consensus workshop participants consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH research society in association with the European society for Pediatric Endocrinology, Lawson Wilkins society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 157:695–700PubMedCrossRef
22.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in men. Diabetologia 28:412–419PubMedCrossRef Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in men. Diabetologia 28:412–419PubMedCrossRef
23.
go back to reference Toniato A, Merante-Boschin I, Opocher G, Pelizzo MR, Schiavi F, Ballotta E (2009) Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann Surg 249:388–391PubMedCrossRef Toniato A, Merante-Boschin I, Opocher G, Pelizzo MR, Schiavi F, Ballotta E (2009) Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann Surg 249:388–391PubMedCrossRef
24.
go back to reference Chiodini I, Morelli V, Salcuni AS, Eller-Vainicher C, Torlontano M, Coletti F, Iorio L, Cuttitta A, Ambrosio A, Vicentini L, Pellegrini F, Copetti M, Beck-Peccoz P, Arosio M, Ambrosi B, Trischitta V, Scillitani A (2010) Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab 95:2736–2745PubMedCrossRef Chiodini I, Morelli V, Salcuni AS, Eller-Vainicher C, Torlontano M, Coletti F, Iorio L, Cuttitta A, Ambrosio A, Vicentini L, Pellegrini F, Copetti M, Beck-Peccoz P, Arosio M, Ambrosi B, Trischitta V, Scillitani A (2010) Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab 95:2736–2745PubMedCrossRef
25.
go back to reference Eller-Vainicher C, Morelli V, Ulivieri FM, Palmieri S, Zhukouskaya VV, Cairoli E, Pino R, Naccarato R, Scillitani A, Beck-Peccoz P, Chiodini I (2012) Bone quality as measured by trabecular bone score (TBS) in patients with adrenal incidentalomas with and without subclinical hypercortisolism. J Bone Miner Res 27:2223–2230PubMedCrossRef Eller-Vainicher C, Morelli V, Ulivieri FM, Palmieri S, Zhukouskaya VV, Cairoli E, Pino R, Naccarato R, Scillitani A, Beck-Peccoz P, Chiodini I (2012) Bone quality as measured by trabecular bone score (TBS) in patients with adrenal incidentalomas with and without subclinical hypercortisolism. J Bone Miner Res 27:2223–2230PubMedCrossRef
Metadata
Title
GH secretion reserve in subclinical hypercortisolism
Authors
Serena Palmieri
Valentina Morelli
Antonio Stefano Salcuni
Cristina Eller-Vainicher
Elisa Cairoli
Volha V. Zhukouskaya
Paolo Beck-Peccoz
Alfredo Scillitani
Iacopo Chiodini
Publication date
01-10-2014
Publisher
Springer US
Published in
Pituitary / Issue 5/2014
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-013-0528-7

Other articles of this Issue 5/2014

Pituitary 5/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.